| The Business Research Company’s report on the Fibrocystic Breast Condition Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the fibrocystic breast condition market in recent years?
The rising prevalence of breast cancer is expected to propel the growth of the fibrocystic breast condition market going forward. Breast cancer is a type of cancer that starts in the cells of the breast, most commonly affecting women. The rising prevalence of breast cancer is driven by factors such as an aging population, unhealthy lifestyles, genetic factors, increasing screening, and environmental exposures. Fibrocystic breast condition (FBC) may increase the risk of breast cancer by creating dense breast tissue, which can promote cellular changes, heightened hormone sensitivity, and prolonged inflammation, potentially creating an environment conducive to cancer development. For instance, in July 2024, according to the American Cancer Society Facts and Figures, a US-based professional organization, the number of new breast cancer cases in the United States is projected to increase from 300,590 in 2023 to 313,510 in 2024. Therefore, the increasing prevalence of breast cancer is driving the growth of the fibrocystic breast condition market.
Expanding Telemedicine Services Driving The Growth Of The Market Due To Increasing Digital Health Adoption
The expanding access to telemedicine services is expected to propel the growth of the fibrocystic breast condition market going forward. Telemedicine services refer to the use of digital communication technologies, such as video calls, mobile apps, and online platforms, to provide remote medical consultations, diagnosis, and treatment. Expanding access to telemedicine services is attributed to the increasing adoption of digital health platforms, improved internet connectivity, and growing patient preference for remote consultations to manage fibrocystic breast conditions efficiently. Fibrocystic breast condition increases the demand for telemedicine services by enabling remote consultations, timely symptom management, and expert guidance, reducing the need for in-person visits and improving patient convenience. For instance, in February 2023, according to Rock Health, a US-based corporation, 80% of respondents in its 2022 survey reported having used telemedicine at some point in their lives, reflecting an increase of 8 percentage points from 72% in 2021. Therefore, the expanding access to telemedicine services is driving the growth of the fibrocystic breast condition market.
Access Your Free Sample of the Global Fibrocystic Breast Condition Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21967&type=smp
What is the projected market size of the fibrocystic breast condition industry, and how is it expected to grow?
The fibrocystic breast condition market size has grown strongly in recent years. It will grow from $6.74 billion in 2024 to $7.17 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to the rising prevalence of breast cancer, rising healthcare expenditure, urbanization, increasing awareness, changing lifestyle, and high disposable income.
The fibrocystic breast condition market size is expected to see strong growth in the next few years. It will grow to $9.10 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to driving up demand for diagnostic tools and treatments, growing government funding, increasing the demand for effective therapies, rising geriatric population, rising initiatives by public and private organizations, and rising research and development activities. Major trends in the forecast period include minimally invasive breast biopsy devices, strategic partnerships and collaborations, a focus on personalized medicine, the integration of artificial intelligence (AI), and technological advancements.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=21967&type=smp
Who are the key players driving competition in the fibrocystic breast condition market?
Major companies operating in the fibrocystic breast condition market are Pfizer Inc., Hitachi Medical Systems, Roche Diagnostics, Merck & Co Inc., Bayer AG, Sanofi SA, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Fujifilm Holdings Corporation, Philips Healthcare, Becton Dickinson and Company, GE Healthcare Technologies Inc., Teva Pharmaceutical Industries Ltd, Hologic Inc., Canon Medical Systems Corporation, Hikma Pharmaceuticals plc, Steris Pharma, Lannett Company Inc., Argon Medical Devices Inc., AdvaCare Pharma USA LLC.
What key trends are expected to drive the fiberscopes market during the forecast period?
Major companies operating in the fibrocystic breast condition market are developing advanced technologies, such as diagnostic devices, to improve diagnostic accuracy and treatment outcomes. A diagnostic device refers to any tool or instrument used to identify, detect, or assess the presence of a medical condition, disease, or health issue. For instance, in August 2024, Izotropic Corporation, a Canada-based medical device company, launched IzoView, a breast CT imaging system designed for diagnosing breast cancer in women with dense breast tissue. The company is pursuing regulatory approval based on a clinical study aimed at demonstrating IzoView’s superiority when used alongside digital breast tomosynthesis (DBT), compared to DBT alone. With high-resolution 3D imaging capabilities and the benefit of not requiring breast compression, IzoView seeks to improve breast cancer detection rates in women with dense breast tissue, a group that is at a higher risk for developing the disease.
Which key geographies are driving the growth of the fibrocystic breast condition market?
North America was the largest region in the fibrocystic breast condition market in 2024. The regions covered in the fibrocystic breast condition market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/fibrocystic-breast-condition-global-market-report
What are the key segments driving growth in the fibrocystic breast condition market?
The fibrocystic breast condition market covered in this report is segmented –
1) By Treatment: Medication, Oral Contraceptives, Fine-Needle Aspiration, Other Treatments
2) By Diagnosis: Mammogram, Ultrasound, Clinical Breast Exam, Other Diagnosis
3) By End-Users: Hospital, Clinic, Other End-Users
Subsegments:
1) By Medication: Over-the-Counter (OTC) Pain Relievers, Prescription Pain Relievers, Hormonal Therapy
2) By Oral Contraceptives: Combination Pills, Progestin-Only Pills
3) By Fine-Needle Aspiration: Ultrasound-Guided Fine-Needle Aspiration, Manual Fine-Needle Aspiration
4) By Other Treatments: Lifestyle And Dietary Changes, Cyst Drainage Procedures, Supportive Therapy, Herbal And Dietary Supplements
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21967
How is the fibrocystic breast condition market defined, and what are its core characteristics?
Fibrocystic breast condition (FBC) refers to a noncancerous condition characterized by lumpiness, tenderness, and pain in one or both breasts due to fibrous tissue and fluid-filled cysts. It is a common benign breast disorder caused by hormonal fluctuations, primarily affecting women of reproductive age. Symptoms may vary throughout the menstrual cycle and typically resolve after menopause.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company |
